Brett Garrison is an associate in the firm’s Intellectual Property group in the Washington, DC office.  Brett focuses on patent litigation, particularly cases brought under the Hatch-Waxman Act.  Brett’s practice extends across the pharmaceutical, biologic and medical device industries.  

Professional Activities

• American Bar Association, Section of Intellectual Property Law and Young Lawyers Division

News

• Axinn’s Client Awarded Attorneys’ Fees in “Exceptional” PIV Case
• Axinn Obtains Favorable Settlement for Pro Bono Client
• Axinn Named a "Legal Lion" for Federal Circuit Patent Win
• Federal Circuit Rules for Axinn Client in Abilify Patent Appeal
• Axinn Honored with Outstanding Achievement Award
• Axinn Obtains Stipulated Summary Judgment of Non-Infringement for Zydus
• Axinn Successfully Obtains Dismissal for Zydus Pharmaceuticals
• U.S. District Court Grants Summary Judgment for Axinn’s Client Zydus in FDA Case
• Axinn Successful in Protecting FDA Approval of Generic Versions of Otsuka’s Abilify
• View More ›

Thought Leadership

• 3 Strategies To Manage Case Scope In ANDA Patent Litigation, Law360, December 10, 2019
• Facilitating Competition and Innovation Isn't Easy: FDA's Latest Hearing On Biologics, FDLI, September 14, 2018
• Obviousness Trends: Get the Edge, Intellectual Property Magazine, June 2015

Events

Education

• JD, cum laude – Washington University School of Law (2014)
• BA, Chemistry – New York University (2009)

Admissions

• District of Columbia
• New York